Highest-materiality recent filing
Z Squared Co-CEO Michelle Burke resigns; David Halabu becomes sole CEO
Michelle Burke resigned as Co-CEO and director on May 22, 2026; no disagreement cited.
Phase 1 goal: 100 MW of AI-ready capacity over 18 months across multiple U.S. sites.
Binding LOI to acquire 100% of Skycore Digital; consideration up to $22M in Series B Preferred with 8% dividend.
Coeptis reverse-merger closes; becomes Z Squared crypto miner; ticker now ZSQR
Merger closed April 24, 2026; former Coeptis biopharma assets distributed pre-close as dividend to CHI.
Z Squared completes pro rata distribution of Coeptis Holdings shares and starts trading under ZSQR
Pro rata distribution of Coeptis Holdings, Inc. common stock to shareholders of record on January 2, 2026.
Coeptis completes reverse merger with Z Squared; shares to trade as ZSQR April 27
Coeptis Therapeutics completes business combination with computing infrastructure firm Z Squared Inc.
Nasdaq approves listing of post-merger Coeptis/Z Squared stock under ticker ZSQR
Nasdaq approved listing of post-merger common stock on the Global Market under symbol ZSQR, subject to merger closing.
Coeptis regains Nasdaq listing compliance; officers exchange underwater options for restricted stock
Nasdaq notified Coeptis on Feb 9, 2026 that it regained compliance with annual meeting requirement for continued listing on Nasdaq Capital Market.
Coeptis stockholders approve merger with Z Squared (94% FOR), name change, spinout, new board
3,472,303 shares voted FOR Merger Proposal (94.0% of votes cast); 225,250 AGAINST; merger with Z Squared approved.
Nasdaq letter on Jan 12, 2026 cites violation of Listing Rules 5620(a) and 5810(c)(2)(G) for failing to hold annual meeting within 12 months of fiscal year end (Dec 31, 2024).
Coeptis Therapeutics to merge with Dogecoin miner Z Squared; biopharma spun out
Coeptis to spin out biopharma; Z Squared becomes wholly-owned subsidiary focused on Dogecoin mining.
Coeptis CSO/CMO Colleen Delaney resigns effective March 24; will consult up to 6 months
Colleen Delaney resigned as Chief Scientific and Medical Officer, effective March 24, 2025.
Following Ms. Burke’s resignation described in Item 5.02(b) above, David Halabu, who had served as a Co-Chief Executive Officer of the Company alongside Ms. Burke since April 24, 2026, will continue to serve as the sole Chief Executive Officer of the Company, effective May 22, 2026.
On May 22, 2026, Michelle Burke notified the Board of Directors (the “Board”) of Z Squared Inc. (the “Company”) of her resignation as Co-Chief Executive Officer and director of the Company, effective May 22, 2026.
On May 22, 2026, Michelle Burke notified the Board of Directors (the “Board”) of Z Squared Inc. (the “Company”) of her resignation as Co-Chief Executive Officer and director of the Company, effective May 22, 2026.
On March 21, 2025, Colleen Delaney submitted her resignation from her role as Chief Scientific and Medical Officer of the Coeptis Therapeutics Holdings, Inc. (the “Company”), effective March 24, 2025.
Max materiality 0.95 · Median 0.68 · Most common event m_and_a